CAR T-Cell Therapy as a Second-Line Treatment for LBCL

News
Video

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Related Videos
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Amit Soni, MD, the Center for Inherited Blood Disorders
Amit Soni, MD, the Center for Inherited Blood Disorders
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
© 2024 MJH Life Sciences

All rights reserved.